MedTrace Logo

Trajectory of Body Composition Identifies LAGC with Cachexia Following NACT

NCT06716593 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2024-12-04

No results posted yet for this study

Summary

This longitudinal, multicentre cohort study included LAGC patients treated with NACT between 01/2010-12/2021. BC measurements including skeletal muscle mass (SMM) and total adipose tissue area (TATA) were evaluated by computed tomography at the third lumbar vertebra at baseline and follow-up imaging. Unsupervised latent class growth mixed models were applied to distinguish potential longitudinal SMM and TATA trajectories for identifying cachexia. The primary study endpoint was overall survival (OS), with secondary endpoints including Recurrence-free survival (RFS), objective response rate (ORR) and safety. Multiple Cox proportional hazards models were used to calculate adjusted hazard ratios (HRs) for survival.

Conditions

  • Locally Advanced Gastric Cancer
  • Trajectory

Sponsors & Collaborators

  • Chang-Ming Huang, Prof.

    lead OTHER

Principal Investigators

  • Chang-Ming Huang, M.D. FACS · Fujian Medical University Union Hospital

Eligibility

Min Age
18 Years
Max Age
84 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-12
Primary Completion
2024-11-27
Completion
2024-11-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06716593 on ClinicalTrials.gov